AGP Executive Report
Last update: 11 hours agoCannabis Research: New York regulators approved a trial comparing oral THC solution VER-01 with placebo for sciatica-related chronic pain, with researchers assessing relief and long-term safety. University of Regina researchers are also studying cannabinoids for post-concussion pain, but the work is still underway. Patient Access: New Jersey signed reforms that raise medical cannabis purchase limits and extend physician authorizations from 90 days to a year. Veterinary Medicine: The FDA says cannabinoid drug CannEpil for canine bone-cancer pain qualifies for a conditional approval pathway; its sponsor is preparing for a November regulatory meeting, with a possible 2027 launch dependent on further requirements. Consumer Safety: A cannabis policy consultancy survey found state-issued QR codes increased respondents’ confidence in regulated products and helped them check compliance and lab results. Hemp Policy: A looming federal restriction on hemp-derived intoxicating THC products puts a reported $28 billion industry at risk, with potential fallout for retailers and manufacturers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
